- Home
- LTRN vs ACXP Comparison
LTRN vs ACXP Comparison
Compare LTRN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | ACXP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 6.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LTRN | ACXP |
|---|---|---|
| Price | $3.50 | $3.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $25.00 | ★ $143.67 |
| AVG Volume (30 Days) | 61.0K | ★ 77.1K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $3.17 |
| 52 Week High | $6.12 | $25.00 |
Technical Indicators
Market Signals| Indicator | LTRN | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 36.67 |
| Support Level | $3.19 | $3.98 |
| Resistance Level | $3.72 | $3.63 |
| Average True Range (ATR) | 0.27 | 0.31 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 32.72 | 2.11 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.